2022
DOI: 10.1016/j.xpro.2022.101391
|View full text |Cite
|
Sign up to set email alerts
|

Localization of T cell clonotypes using the Visium spatial transcriptomics platform

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
26
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 30 publications
(34 citation statements)
references
References 8 publications
2
26
0
Order By: Relevance
“…Moreover, imaging tools can be leveraged to identify cells or tissue areas expressing specific surface markers that, coupled with gene expression, can guide downstream analyses [ 129 ]. Sudmeier and colleagues successfully paired spatial transcriptomics with TCR-seq by adapting the 10X Visium experimental protocol, revealing how tumor infiltrating CD8 + T-cell subpopulations have different phenotypes and localize in specific niches within brain metastasis tumor core or parenchyma, fostering the development of more specific immunotherapeutic strategies [ 42 , 130 ]. Recently, a novel methodology, referred as to Slide-TCR-seq, has been developed by Liu et al for sequencing whole transcriptomes and TCRs within intact tissue [ 42 , 43 , 130 ].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Moreover, imaging tools can be leveraged to identify cells or tissue areas expressing specific surface markers that, coupled with gene expression, can guide downstream analyses [ 129 ]. Sudmeier and colleagues successfully paired spatial transcriptomics with TCR-seq by adapting the 10X Visium experimental protocol, revealing how tumor infiltrating CD8 + T-cell subpopulations have different phenotypes and localize in specific niches within brain metastasis tumor core or parenchyma, fostering the development of more specific immunotherapeutic strategies [ 42 , 130 ]. Recently, a novel methodology, referred as to Slide-TCR-seq, has been developed by Liu et al for sequencing whole transcriptomes and TCRs within intact tissue [ 42 , 43 , 130 ].…”
Section: Introductionmentioning
confidence: 99%
“…Sudmeier and colleagues successfully paired spatial transcriptomics with TCR-seq by adapting the 10X Visium experimental protocol, revealing how tumor infiltrating CD8 + T-cell subpopulations have different phenotypes and localize in specific niches within brain metastasis tumor core or parenchyma, fostering the development of more specific immunotherapeutic strategies [ 42 , 130 ]. Recently, a novel methodology, referred as to Slide-TCR-seq, has been developed by Liu et al for sequencing whole transcriptomes and TCRs within intact tissue [ 42 , 43 , 130 ]. The unprecedented opportunity to explore the TCR repertoire dynamics in their spatial context will be instrumental in understanding how the anatomical distribution of T cells and their partners shapes immune response, particularly within the dysregulated TME.…”
Section: Introductionmentioning
confidence: 99%
“…Current methods to integrate spatial location and single-cell transcriptomics have difficulty additionally obtaining full-length immune receptor information for cells at high throughput. Despite ongoing work to generate experimental data sets that integrate cell location, transcriptome and immune receptor sequence, these datasets currently only contain heavy chain information for a few cells (e.g., roughly 27 T cells for an entire image) ( Hudson and Sudmeier, 2022 ). These challenges have thereby prevented the development of computational methods capable of integrating spatial information into clonal relationships.…”
Section: Resultsmentioning
confidence: 99%
“…Despite these challenges this is the only platform, among those compared, that does not require the use of targeted RNA probes, thereby enabling capture of all intrinsic RNA molecules with poly-A sequences. This can be particularly valuable for profiling transcripts whose nucleotide sequences are variable, for example, TCR or BCR [39].…”
Section: Discussionmentioning
confidence: 99%